Search details
1.
An NK-like CAR T cell transition in CAR T cell dysfunction.
Cell
; 184(25): 6081-6100.e26, 2021 12 09.
Article
in English
| MEDLINE | ID: mdl-34861191
2.
Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells.
Immunity
; 56(10): 2388-2407.e9, 2023 Oct 10.
Article
in English
| MEDLINE | ID: mdl-37776850
3.
Human epigenetic and transcriptional T cell differentiation atlas for identifying functional T cell-specific enhancers.
Immunity
; 55(3): 557-574.e7, 2022 03 08.
Article
in English
| MEDLINE | ID: mdl-35263570
4.
Potentiating adoptive cell therapy using synthetic IL-9 receptors.
Nature
; 607(7918): 360-365, 2022 07.
Article
in English
| MEDLINE | ID: mdl-35676488
5.
Decade-long leukaemia remissions with persistence of CD4+ CAR T cells.
Nature
; 602(7897): 503-509, 2022 02.
Article
in English
| MEDLINE | ID: mdl-35110735
6.
Enhancing chimeric antigen receptor T cell therapy by modulating the p53 signaling network with Δ133p53α.
Proc Natl Acad Sci U S A
; 121(10): e2317735121, 2024 Mar 05.
Article
in English
| MEDLINE | ID: mdl-38408246
7.
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells.
Nature
; 558(7709): 307-312, 2018 06.
Article
in English
| MEDLINE | ID: mdl-29849141
8.
Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells.
Mol Ther
; 31(8): 2309-2325, 2023 08 02.
Article
in English
| MEDLINE | ID: mdl-37312454
9.
Publisher Correction: Potentiating adoptive cell therapy using synthetic IL-9 receptors.
Nature
; 612(7938): E10, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-36380037
10.
Author Correction: Decade-long leukaemia remissions with persistence of CD4+ CAR T cells.
Nature
; 612(7941): E22, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-36477542
11.
Dysregulated mTORC1 renders cells critically dependent on desaturated lipids for survival under tumor-like stress.
Genes Dev
; 27(10): 1115-31, 2013 May 15.
Article
in English
| MEDLINE | ID: mdl-23699409
12.
B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy.
Br J Haematol
; 193(4): 851-855, 2021 05.
Article
in English
| MEDLINE | ID: mdl-33713436
13.
The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion.
Nat Commun
; 15(1): 3933, 2024 May 10.
Article
in English
| MEDLINE | ID: mdl-38730243
14.
Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma.
Sci Adv
; 9(2): eade2526, 2023 Jan 13.
Article
in English
| MEDLINE | ID: mdl-36630514
15.
Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy.
Sci Transl Med
; 15(714): eadi1145, 2023 09 20.
Article
in English
| MEDLINE | ID: mdl-37651540
16.
Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma.
Blood Adv
; 7(14): 3416-3430, 2023 07 25.
Article
in English
| MEDLINE | ID: mdl-37058474
17.
Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy.
Blood Cancer Discov
; 4(2): 118-133, 2023 03 01.
Article
in English
| MEDLINE | ID: mdl-36413381
18.
Next-Generation CAR T-cell Therapies.
Cancer Discov
; 12(7): 1625-1633, 2022 07 06.
Article
in English
| MEDLINE | ID: mdl-35417527
19.
BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia.
J Clin Invest
; 131(16)2021 08 16.
Article
in English
| MEDLINE | ID: mdl-34396987
20.
Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells.
Nat Med
; 27(5): 842-850, 2021 05.
Article
in English
| MEDLINE | ID: mdl-33888899